TI
ZVRA icon

Trexquant Investment’s Zevra Therapeutics ZVRA Stock Holding History

Trexquant Investment’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-209,704
Closed -$1.88M – 2101
2025
Q4 		$1.88M Sell
209,704
-93,159
-31% -$881K 0.02% 1011
2025
Q3 		$2.88M Buy
+302,863
New +$3.04M 0.03% 761

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Trexquant Investment's ZVRA Position: Q1 2026 in Review

Trexquant Investment sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 209,704 shares — an estimated $1.88M sold.

Trexquant Investment first reported a position in ZVRA in Q3 2025 and held it in 2 quarters. The position peaked at $2.88M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Trexquant Investment reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Trexquant Investment sold 209,704 Zevra Therapeutics shares in Q1 2026, an estimated $1.88M.
  • Trexquant Investment first reported a position in Zevra Therapeutics in Q3 2025 and held it in 2 quarters.
  • Trexquant Investment's Zevra Therapeutics position peaked at $2.88M in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.